AI at your fingertips: Pathomation and Aiosyn expand partnership to bring trusted AI solutions to pathology labs
AiosynQC and IVDR-certified Aiosyn Mitosis Breast are now available through Pathomation’s AI Marketplace, building on their AWAKE project collaboration to transform kidney diagnostics with AI.
Antwerp, Belgium, and Nijmegen, Netherlands – August 2025 – Pathomation, a leading provider of digital pathology software solutions, and Aiosyn, a pioneering innovator in AI-powered pathology for cancer and kidney disease, announced an expansion of their strategic collaboration. This extended partnership includes the integration of AiosynQC, Aiosyn’s slide quality control, and Aiosyn Mitosis Breast, an IVDR-certified algorithm for mitosis counting, into Pathomation’s AI Marketplace, offering pathology labs seamless access to trusted AI tools within their existing workflows. Additionally, Pathomation and Aiosyn continue their joint development on the Eurostars-funded AWAKE project, focused on AI-powered solutions for renal diagnostics.
“Integrating Aiosyn’s mitotic counting algorithm, which is IVDR-certified, into our AI Marketplace marks a significant milestone in delivering clinically validated AI tools directly to pathologists,” said Rudy Hovelinck, CEO of Pathomation. “The algorithm is a particularly useful tool for pathologists, both saving time spent on tedious mitosis counting and increasing consistency. This integration in the Pathomation software opens new possibilities for labs to access advanced AI with full confidence, all within a flexible, interoperable platform that fits their unique workflow needs.”
The AI Marketplace allows pathologists and labs to easily discover, test, and deploy AI algorithms without the complex, time-consuming IT integrations traditionally required.
“We’re excited to bring AiosynQC and our IVDR-certified Aiosyn Mitosis Breast to Pathomation’s AI Marketplace,” said David Tellez, CTO of Aiosyn. “This supports our mission to make trusted AI tools more accessible to pathologists and improve patient care.”
Meanwhile, the AWAKE project continues to make strides in developing AI-driven algorithms for objective and quantitative renal biopsy analysis. Funded by a €1.6M Eurostars grant, the project aims to enhance diagnostic precision and improve outcomes for patients with chronic kidney disease, a condition affecting 850 million people globally.
Looking ahead, Pathomation and Aiosyn are focused on expanding their collaboration within Pathomation’s AI Marketplace, making clinically validated AI tools like the IVDR-certified Aiosyn Mitosis Breast algorithm readily available to pathologists worldwide. This seamless integration empowers labs to adopt AI-powered diagnostic support faster, more securely, and with greater flexibility.
About Pathomation
Pathomation is a Digital Pathology software developer and manufacturer, located in Antwerp, Belgium. Pathomation commercialises products for Educational, Research and Diagnostic IVD use and provides custom development and expert project services for OEM companies and the pharmaceutical sector. Pathomation is active in the promotion, marketing and commercialisation of its products to end users, direct or through distributors, around the globe and provides scientific and technical support.
Pathomation’s digital pathology software solutions reduce laboratory expenses,
boost operational efficiency, enhance productivity, aid in better treatment decisions
and ultimately improve patient care.
Visit our website www.pathomation.com and follow us on LinkedIn for more information.
Press contact: info@pathomation.com
About Aiosyn
Based in the Netherlands, Aiosyn develops precision pathology software for breast cancer and kidney disease, integrating its solutions into standard pathology workflows. Aiosyn has been built upon more than 20 years of research experience in the field of pathology and is rooted in pathology practice.
For full product details, visit AiosynQC, Aiosyn Mitosis Breast, and the NephroPath platform.
SOURCE: Pathomation
